Search Results for "Cytosar-U"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Cytosar-U. Results 11 to 14 of 14 total matches.
See also: cytarabine
Decitabine (Dacogen) for Myelodysplastic Syndromes
The Medical Letter on Drugs and Therapeutics • Nov 06, 2006 (Issue 1247)
(Cytosar-U, and others) plus an anthracyDRUG FORMULATION DOSAGE ...
Decitabine (Dacogen - MGI Pharma), a pyrimidine nucleoside analog of cytidine, was approved by the FDA as an orphan drug for treatment of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hemopathies that decrease production of normal blood elements (red cells, white cells and platelets) and are associated with a risk of progression to acute leukemia.
Drugs of Choice for Cancer
Treatment Guidelines from The Medical Letter • Mar 01, 2003 (Issue 7)
; periphadenosine; 2-CdA; Leustatin – eral neuropathy with high doses
Ortho-Biotech)
Cytarabine HCl (Cytosar-U ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Drugs of Choice for Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • Mar 31, 1995 (Issue 945)
*
Cytarabine HCl (Cytosar-U
− Pharmacia, and others)
Nausea and vomiting; diarrhea; anaphylaxis; sudden ...
Gemtuzumab for Relapsed Acute Myeloid Leukemia
The Medical Letter on Drugs and Therapeutics • Jul 24, 2000 (Issue 1083)
treatment of AML is combination chemotherapy
with cytarabine (Cytosar-V, and others) and an anthracycline ...
Gemtuzumab ozogamicin, a monoclonal antibody bound to a cytotoxic antibiotic, has been approved by the FDA for treatment of patients with CD33-positive acute myeloid leukemia (AML) in first relapse who are more than 60 years old and may not be able to tolerate cytotoxic chemotherapy